ACE2 and infection: A recent study using an engineered human tissue system demonstrated that soluble human ACE2 can reduce viral growth in vitro and inhibit SARS-CoV-2 infection in blood vessels and human kidney organoids on the early stages of infection 102, suggesting exogenous ACE2 could block early entry of SARS-CoV-2.